Smooth sailing for NeuroDiscovery
Tuesday, 22 July, 2008
Perth biotech NeuroDiscovery has successfully completed an early stage trial of its neuropathic pain candidate NSL-043.
The compound, previously developed by another company for inflammatory disease, was successful in single ascending dose clinical trials and has now completed a multiple ascending dose trail.
The company said the compound's adverse event profile demonstrated good safety and tolerability.
NeuroDiscovery is also investigating the development of antagonists of the connexin and pannexin families of gap junction proteins.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
